Provided by Tiger Trade Technology Pte. Ltd.

TEMA ONCOLOGY ETF

40.78
+0.65291.63%
Post-market: 40.76-0.0229-0.06%19:30 EDT
Volume:12.96K
Turnover:528.51K
Market Cap:205.14M
PE:- -
High:41.00
Open:40.29
Low:40.17
Close:40.13
52wk High:47.00
52wk Low:29.28
Shares:5.03M
Float Shares:5.03M
Volume Ratio:0.34
T/O Rate:0.26%
Dividend:0.02
Dividend Rate:0.05%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Legend Biotech Director Makes Bold Move With Fresh Insider Stock Sale

TIPRANKS
·
Oct 02

Revolution Medicines Chief Development Officer Alan B. Sandler Disposes of USD 1,264,082 in Common Shares

Reuters
·
Oct 02

Legend Biotech Director Corazon D. Sanders Sells 27,370 Shares for $258,920.20

Reuters
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Oct 02

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Oct 02

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

Legend Biotech Launches Inaugural Elite Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

THOMSON REUTERS
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

Paramount Names Kreiz as Co-CEO as Warner Bros. Deal Nears Completion

Deep News
·
Oct 01

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
Oct 01

Eli Lilly - Achieve-4: Foundayo Shows 16% Lower Mace-4 and 23% Lower Mace-3 Risk vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Eli Lilly - Foundayo Shows Smaller Egrf Reduction and Greater Albuminuria Reduction vs Insulin Glargine

THOMSON REUTERS
·
Oct 01